<DOC>
	<DOCNO>NCT02712567</DOCNO>
	<brief_summary>SARC021C nonrandomized , open-label , multicenter , continuation study design provide access TH-302 patient currently receive benefit single agent TH-302 therapy part Phase III TH-CR-406/SARC021 study .</brief_summary>
	<brief_title>SARC021C : A Continuation Study TH-CR-406/SARC021</brief_title>
	<detailed_description>The goal study provide continuation therapy TH-302 patient soft tissue sarcoma obtain response stabilization disease prior treatment TH-CR-406/SARC021 protocol . After write informed consent obtain eligibility establish , patient receive study drug part continuation study . Patients receive treatment study long clinical benefit experience unacceptable toxicity .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<criteria>Ability understand purpose risk study sign write informed consent form approve investigator 's IRB/Ethics Committee . Previously enrol THCR406/SARC021 protocol benefit treatment . Study investigator deems continue participation appropriate base overall health patient . Any criterion study discontinuation meet . Concomitant disease condition could interfere conduct study , would , opinion investigator , pose unacceptable risk subject study . Unwillingness inability comply study protocol reason .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>